Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Theratyping Trial in Cystic Fibrosis
NCT03587961Phase 1Recruiting
- Start
- Aug 2019
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tezacaftor + ivacaftor, lumacaftor + ivacaftor and ivacaftor in cystic fibrosis (CF) (3 arms). Primary endpoint: Spirometry at 32 weeks. Started Aug 2019; status: recruiting.
02
Drugs
tezacaftor + ivacaftorlumacaftor + ivacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03587961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587961.